BASF pays $416,000 fine, cuts NAFLD claims for fish oil product as FTC consent decree is approved

By Hank Schultz contact

- Last updated on GMT

©Getty Images - serggn
©Getty Images - serggn

Related tags: Omega-3s, EPA and DHA, Fish oils, NAFLD

A final consent degree has been approved between BASF and a second company and the US Federal Trade Commission to settle a case concerning the use of a fish oil supplement in the treatment of non alcoholic fatty liver disease (NAFLD).

The complaint cited parent company BASF SE, its North American arm, and DIEM Labs, which the complaint said had entered into a marketing relationship with BASF.  The complaint concerns two BASF products, Hepaxa and Hepaxa PD.  

Hepaxa is a highly concentrated form of  fish oil, delivering 460 mg of EPA and 380 mg of DHA omega-3 fatty acids per serving.  The products debuted in the US in 2018 and were on the market a year later in Europe​. Both were marketed as products that could “help tens of millions of patients manage Non-Alcoholic Fatty Liver Disease.” ​ The PD product was aimed at children.

BASF has agreed to pay a $416,000 fine and cease making its allegedly false and misleading claims that could significantly cut liver fat in cases of NAFLD.  The company had based its claims with a study published in the journal Nutrients​ in 2018​.

FTC doesn’t agree with statistical basis of study’s conclusion

That study, which included 176 subjects and stretched over 24 weeks, found that liver fat declined about equally in both the placebo and fish oil arms of the study.  But it  used a statistical technique known as a regression analysis to associate  the highest red blood cell levels of omega-3s achieved by subjects in the experimental group with a trend toward liver fat reduction. 

“The liver fat content of patients was significantly reduced amongst both placebo and intervention arms, thereby masking any effects omega-3 may have had on the fat content of the liver.  . . . In a post-hoc analysis significant placebo adjusted reductions in liver fat were seen in sub-populations with a high FLI  (Fatty Liver Index) score,”​ the study concluded.

The FTC wasn’t buying the notion that the post hoc analysis amounted to support for a ‘clinically proven’ claim of reduction of liver fat in NAFLD patients.

“BASF and DIEM couldn’t back up serious claims about how Hepaxa capsules would help adults and kids with liver disease,”​ said Daniel Kaufman, Acting Director of the FTC’s Bureau of Consumer Protection. “Companies can’t cherry-pick data and need to be upfront about the science behind—or not behind—their products.”

FTC said the fine will be used to reimburse consumers that may have bought the products.  The website for the product has been taken down, and in several sales portals the Hepaxa products are listed as ‘out of stock.’

Related news

Related products

show more

Related suppliers

Follow us

Products

View more

Webinars